Aptose Biosciences Inc. (NASDAQ:APTO) Receives $9.40 Consensus Target Price from Analysts

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) has been given an average recommendation of “Buy” by the six brokerages that are presently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have issued a report on the stock in the last year is $9.40.

A number of brokerages have recently issued reports on APTO. Zacks Investment Research raised Aptose Biosciences from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research report on Tuesday, November 16th. HC Wainwright upped their price target on Aptose Biosciences from $9.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, November 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aptose Biosciences in a research report on Wednesday, November 17th.

In related news, VP Rafael Bejar purchased 10,000 shares of Aptose Biosciences stock in a transaction that occurred on Friday, November 19th. The stock was purchased at an average price of $2.56 per share, for a total transaction of $25,600.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 8.41% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC acquired a new stake in Aptose Biosciences in the 3rd quarter valued at about $34,000. Two Sigma Investments LP acquired a new stake in Aptose Biosciences in the 3rd quarter valued at about $477,000. UBS Group AG raised its holdings in Aptose Biosciences by 102.1% in the 3rd quarter. UBS Group AG now owns 18,478 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 9,333 shares during the last quarter. Millennium Management LLC raised its holdings in Aptose Biosciences by 119.6% in the 3rd quarter. Millennium Management LLC now owns 692,531 shares of the biotechnology company’s stock valued at $1,510,000 after acquiring an additional 377,238 shares during the last quarter. Finally, Man Group plc raised its holdings in Aptose Biosciences by 77.0% in the 3rd quarter. Man Group plc now owns 260,836 shares of the biotechnology company’s stock valued at $569,000 after acquiring an additional 113,456 shares during the last quarter. Institutional investors own 63.64% of the company’s stock.

NASDAQ:APTO traded down $0.05 during trading hours on Thursday, reaching $2.40. The company’s stock had a trading volume of 794,628 shares, compared to its average volume of 1,948,004. The company has a market capitalization of $213.48 million, a P/E ratio of -3.81 and a beta of 1.62. Aptose Biosciences has a 12 month low of $2.02 and a 12 month high of $7.27. The stock has a 50 day moving average price of $2.38 and a two-hundred day moving average price of $3.15.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings data on Thursday, November 11th. The biotechnology company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.04. During the same quarter in the prior year, the company posted ($0.15) earnings per share. On average, analysts expect that Aptose Biosciences will post -0.66 EPS for the current fiscal year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Featured Story: What is a Derivative?

Analyst Recommendations for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.